# Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

> **NCT02418754** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 505 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** REGN2176-3
- **DRUG:** Intravitreal Aflibercept Injection (IAI)

## Key facts

- **NCT ID:** NCT02418754
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-05
- **Primary completion:** 2016-08-17
- **Final completion:** 2017-04-03
- **Target enrollment:** 505 (ACTUAL)
- **Why stopped:** No additional efficacy seen with REGN2176-3 over aflibercept alone
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418754, "Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02418754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*